FluBlok: Clinical Trials

4 trials of FluBlok, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4
Phase 11Completed 1
Phase 31Completed 1

Follow FluBlok: new trials by email Literature Review of FluBlok trials Research Report on FluBlok

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults
Recombinant Influenza HA Vaccine (H5N1) - Influenza
Phase 2CompletedUMN Pharma Inc.872010-10-012011-02-08
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
UMN-0501 - Influenza, Virus Diseases
Phase 2CompletedUMN Pharma Inc.902009-10-012010-02-08
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
Influenza Vaccination - Influenza
Phase 1 / Phase 2CompletedProtein Sciences Corporation1562006-10-012009-12-17
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
Influenza Vaccine, recombinant Hemagglutinin - Influenza
Phase 2 / Phase 3CompletedProtein Sciences Corporation4592004-11-012010-01-12

Conditions studied

Influenza, Human (4)  ·  Influenza in Birds (1)  ·  Virus Diseases (1)

Sponsors

Protein Sciences Corporation (2)  ·  UMN Pharma Inc. (2)

Countries

Japan (2)  ·  United States (2)

Top investigators

James C King, MD (1)  ·  John Treanor, MD (1)  ·  Suminobu Ito, MD, PhD (1)  ·  Tetsuo Nakayama, MD, PhD (1)

Results publications

PMID 17426277, PMID 19716456, PMID 26787832, PMID 28325769